Complex interrelationships exist between the four pancreatic islet cell types and their respective secretory products, insulin, glucagon, somatostatin, and pancreatic polypeptide. These hormones are known to interact with the different islet cells and modulate their functions. Insulin inhibits glucagon secretion from the A cell both in vivo and in vitro and, in states of insulin deficiency, high glucagon levels are observed that are normalized by insulin replacement. To determine if insulin also regulates glucagon biosynthesis, we studied its effects on glucagon gene expression. Our studies indicate that insulin, in a dose-dependent fashion decreases steady-state glucagon mRNA levels in a clonal hamster islet cell line, In-Rl-G9; this decrease is secondary to an inhibition of glucagon gene transcription as assessed by transcriptional run-on assays and does not involve detectable changes in mRNA stability. Inhibition of glucagon gene transcription is accompanied by corresponding decreases in glucagon immunoreactivity in both cell extracts and medium. We conclude that insulin may not only regulate glucagon secretion but also glucagon gene expression.
Introduction
The fact that the four different pancreatic islet cell types A (glucagon), B (insulin), D (somatostatin), and PP (pancreatic polypeptide) are not randomly distributed within an islet, but, on the contrary, are highly organized has led to the hypothesis that such an architecture might serve a functional role and that contiguous cells might influence one another (1) (2) (3) . In a number of pioneering studies, Samols successively showed that glucagon, the hormonal product of the A cell had stimulatory effects on insulin secretion (4) and conversely that insulin inhibited glucagon release (5) . A larger concept of the interrelationships existing between the different islet cells emerged when somatostatin was shown to potently suppress insulin (6) and glucagon secretion (7) and glucagon to enhance somatostatin release (8) . Although these interactions between the A, B, and D cells and their secretory products are now well accepted, it is not entirely clear whether they are mediated through paracrine mechanisms, direct sequential vascular perfusion or both. The relative importance of the vascular compartment has recently been illustrated by an increase in gluca-gon secretion resulting from experimental intravascular depletion of insulin (by anti-insulin antibodies infusion) (9) . In addition, Samols, using rat pancreata perfused both anterogradely and retrogradely elegantly underlined the functional roles of the vascular compartment and of the direction of the blood flow in mediating the effects of insulin on glucagon secretion and of glucagon on somatostatin release (10) .
A relevant clinical correlate of these experimental observations is the high glucagon levels that characterize untreated diabetes mellitus in humans and animals (11, 12) . Hyperglucagonemia is indeed a hallmark of both type I and type II diabetes in man (13) . Although fluctuations in blood glucose levels have been proposed to be the main determinant in the regulation of glucagon secretion (14) , more recent data have shown that these effects are mostly secondary to the increased release of insulin, which appears to exert its effects independently of ambient glucose concentration (15) . The tonic inhibition of glucagon secretion by insulin and the chronically elevated glucagon levels in states of insulin deficiency has led to the hypothesis that insulin might not only affect the release ofglucagon but might also be involved in the control of glucagon biosynthesis (3) . Insulin is known to affect the levels of certain cellular mRNAs through a direct interaction with its cell surface receptors (16, 17) . To better understand insulin action on the A cell, we studied the effects of insulin on glucagon gene expression. Using a clonal hamster islet cell line, In-R l-G9, producing high levels ofglucagon and no detectable insulin (18) we show here that insulin decreases steady-state glucagon mRNA levels in a dose-dependent fashion and that this decrease reflects a direct inhibition of glucagon gene transcription.
Methods
Cell culture. In-R 1 -G9 cells were previously cloned from hamster insulinoma cells (In-l ll-R1) (18) . These cells grow in monolayers in RPMI 1640 at a glucose concentration of 1,800 mg/liter, supplemented with 10% newborn calf serum (NCS), 100 U/ml penicillin and 100 Ag/ml streptomycin. 3 X 106 cells were plated on 100 mm dishes for RNA extraction and experiments were run 3-4 d later. Cells were incubated with porcine insulin in RPMI 1640 supplemented with 0.5% BSA.
For all experimental conditions, cells were switched from RPMI 1640 medium containing 10% NCS to the RPMI 1640 with 0.5% BSA at time -l h.
Northern blot analysis. Cells were lysed in guanidine thiocyanate and RNA was extracted through a cesium chloride gradient by centrifugation (19 (19) .
Nuclear run-on experiments. Gene transcription rates were determined by quantification of nascent glucagon and ,B-actin RNA transcripts in nuclei (the equivalent of 300-350 Atg of DNA) from control and insulin-treated cells, as previously described (20) . Briefly, cells were washed with ice-cold PBS and scraped into 2 ml of 0.25 M sucrose, 20 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 0.1% N P-40, I mM dithiothreitol. The nuclei were isolated by disrupting the cells in a Dounce homogenizer and pelleted through a step gradient of I ml 0.3 M sucrose, 20 mM Tris-HCI (pH 7.9) layered over 1.5 ml of 0.5 M sucrose, 20 mM Tris-HCl (pH 7.9). Nuclear transcripts were labeled with [32P]a-UTP and extracted as described (20) . Labeled RNA (> 90% of the counts were precipitable by trichloroacetic acid) was hybridized to an excess of cloned specific DNA (5 Mg) (rat glucagon cDNA [21] and as control, chicken ,l-actin cDNA [20] ) bound to nitrocellulose using a slot-blot apparatus. Filters were prehybridized and hybridized for 48 h at 60°C (20) .
Glucagon mRNA stability. 
Results
Phenotypic expression ofIn-RI-G9. In-Rl-G9, a glucagon-secreting clonal hamster islet cell line has recently been isolated (18) and characterized (18, 23) . This cell line was chosen for the stable and high expression level of the glucagon gene and for the absence of insulin and somatostatin production, as assessed by both mRNA analysis and radioimmunoassay (23) . However, when cells were passaged multiple times, measurable amounts of insulin immunoreactivity were occasionally detected in the culture medium (up to 0.5 ng/2 X lIO cells/24 h); these cells were not considered for further experiments.
Glucagon biosynthesis is inhibited by insulin. To first determine if insulin could be affecting glucagon biosynthesis, we monitored glucagon-like immunoreactivity from control and insulin-treated In-Rl-G9 cells in both medium and cell extracts. 5 X 10 cells were incubated with 10-8 M insulin for 6, 12, and 24 h. There was a time-dependent decrease in glucagon immunoreactivity in both medium and cell extracts (Fig.  1) ; however, more pronounced decreases were noted at 6 h in the medium compared to cell extracts; insulin inhibition of glucagon secretion from In-Rl-G9 cells, in addition to decreases in biosynthesis, is probably the explanation for this observation. At 24 h, the decrease in glucagon immunoreactivity reached 64% of control values in cell extracts and 69% in medium.
A progressive increase in glucagon-like immunoreactivity was observed between 6 h and 24 h in both control cell extracts and culture medium. Such an increase was expected in the medium since it probably did result from accumulated peptide secreted over time. By contrast, the twofold increase measured in cell extracts could have been due to the removal of low concentrations of insulin present in NCS with a consequent disinhibition of glucagon biosynthesis. Insulin decreases steady-state glucagon mRNA levels. To further investigate the mechanisms by which insulin affects glucagon biosynthesis, insulin action on glucagon gene expression was examined at the mRNA level. Insulin was added to In-Rl-G9 cells at different concentrations in RPMI 1640 medium containing 0.5% BSA; these cells can be maintained in serum-free medium for at least 48 h without significant cell loss (data not shown). Total RNA was extracted from the cells after a 24-h incubation period with insulin, separated by electrophoresis on agarose gel and analyzed by Northern transfer. Insulin decreased glucagon mRNA levels in a dose-dependent manner (Fig. 2) . At the lowest concentration, 1011 M, glucagon mRNA levels were at 70% of the control values and further reductions down to 22% were seen as the concentrations of insulin were increased to 10-8M. Between 10-8 and 10-6 M insulin no change in the abundance of glucagon mRNA levels could be detected. Others have also noted that some effects of insulin do not change or even decrease at markedly high hormone concentrations (24, 25) .
The relative quantity of actin mRNA was also assessed to control for the amount of total RNA electrophoresed in each lane and for the specificity of the insulin effect; the level of actin mRNA was found to be comparable (within 20% for each experimental condition) (Fig. 1) . The values of the intensity of the glucagon mRNA signal given by laser densitometry was thus corrected by the relative amount of actin mRNA in its respective lane.
To investigate the time-dependency of the insulin-mediated decrease in glucagon mRNA, we incubated In-Rl-G9 cells in the presence of insulin (10-8 M) for 6, 14, 24, and 48 h. (Fig.  4) . In comparison, the K3-actin signal remained unchanged and pGem 3 elicited no signal. The addition of a-amanitin at 2 ,ug/ml to the nuclei (to inhibit RNA polymerase II [26] ) abolished transcription, indicating that the signals observed resulted from RNA polymerase II-mediated gene transcription.
Glucagon mRNA half-life was then compared in both control and insulin-treated cells. Actinomycin D (5 ,ug/ml), which completely blocks RNA synthesis in islet cells (27) In-RlI-G9 cells were incubated with 10-8 M insulin in RPMI 1640 with 0.5% (as detailed in Fig. 2) (Fig. 5) . Glucagon-specific mRNA disappearance rates were similar in both control and insulin-treated cells. The half-life of glucagon mRNA was estimated to be -12-14 h, similar to what was previously found in a rat islet cell line (20) . These results indicate that insulin effects on glucagon gene expression are mediated predominantly or entirely at the level oftranscription of the glucagon gene and not by modulating the stability of the mRNA.
Discussion
Our results show that insulin induces a rapid and substantial decrease in glucagon gene expression and that this effect occurs at the level oftranscription ofthe gene. Previous studies indicate that insulin decreases glucagon secretion both in vivo and in vitro independently of glucose concentration (9, 10, 15) . In the described experimental system, in the presence of 180 mg/dl of glucose, both glucagon secretion (18) and glucagon gene expression are modulated by insulin; we, indeed, observe, in the presence of insulin a dose-dependent decrease in steady-state glucagon mRNA levels; this effect is already detected at an insulin concentration of 10-11 M (similar to the concentrations previously shown to affect phosphoenolpyruvate carboxykinase (PEPCK) gene expression [16] ) and maximal effects are seen at 10-8 M. Of note, Takaki reported a decrease in glucagon secretion from In-R 1 -G9 cells at even lower insulin concentrations (l0-14 M) (18) ; whether the process of glucagon secretion from In-R 1 -G9 cells is more sensitive to insulin than glucagon gene transcription is unclear; this differential response might also be explained by concentrations of contaminating insulin (produced by the cells) not (37, 38) ; it is conceivable that preexisting nuclear factors that bind to these sequences, are modified by a cascade of phosphorylation-dephosphorylation reactions induced by insulin; modulating the phosphorylation state of trans-acting factors has recently been shown to be important in regulating transcription of specific genes (39, 40) . It is interesting to note that, although the cisacting DNA sequences responsible for the tissue-specific expression of the glucagon gene appear to be different in the A cell of the pancreas compared to the L cell of the intestine (41, 42) , the same DNA element could mediate insulin effects on glucagon gene regulation in these two tissues. Indeed, insulin effects on glucagon secretion do not appear to be limited to the A cell of the pancreatic islets, but are probably also observed on the canine gastric A cells (31) and the intestinal L cells (43) . This model thus offers the possibilities to identify discrete DNA sequences through which insulin exerts negative regulatory effects and the trans-acting factors interacting with them. It must be pointed out, however, that In-Rl-G9 cells are clonal hamster islet cells, originally immortalized by the BK virus. Although In-Rl-G9 cells can be considered as a useful model to study the molecular mechanisms of glucagon gene expression our results should be interpreted with reservations in regard to the transformed state of these cells.
Finally, our data may provide a potential explanation for the hyperglucagonemia observed in insulin deficiency characteristic of diabetes mellitus; the high glucagon levels seen in these conditions can be indeed rapidly and completely corrected by adequate insulin therapy. We hypothesize that the rapid restoration of normal glucagon levels in diabetic states results not only from an inhibition of glucagon hormone secretion but also from a direct inhibition of glucagon gene transcription.
